ba ƙananan ƙwayoyin cutar kansar huhu ba

Ciwon huhu mara ƙanƙanta (NSCLC) nau'in ciwon huhu ne na kowa. Zaɓuɓɓukan jiyya na NSCLC sun bambanta kuma sun dogara da dalilai da yawa, gami da matakin ciwon daji, lafiyar majiyyaci gabaɗaya, da takamaiman maye gurbi a cikin ƙwayar cuta. Wannan jagorar yana ba da bayyani game da manyan hanyoyin magance NSCLC, wanda ya fara daga tiyata da radiation far zuwa maganin da aka yi niyya da rigakafi, ƙarfafa marasa lafiya da masu kulawa tare da ilimin da za su yanke shawarar da aka sani.Fahimtar Ciwon Kankara mara Ƙananan ƙwayar cuta.Ciwon huhu mara ƙanƙanta (NSCLC) rukuni ne na cututtukan huhu da ke yin irin wannan hanya. Babban nau'ikan NSCLC sun haɗa da adenocarcinoma, squamous cell carcinoma, da manyan ƙwayoyin cuta. Madaidaicin ganewar asali, gami da matakan gwaji da gwajin kwayoyin halitta, yana da mahimmanci don tantance dabarun jiyya mafi inganci. Cibiyar Nazarin Ciwon daji ta Shandong Baofa ta sadaukar da ita don binciken ciwon daji da haɓaka sabbin hanyoyin jiyya, ƙarin koyo a https://baofahospital.com.Staging na NSLCCNSCLC an tsara ta ta amfani da tsarin TNM (Tumor, Node, Metastasis). Matakin ya bayyana girman da wurin da ciwon farko (T) yake, ko ciwon kansa ya yadu zuwa nodes na lymph na kusa (N), da kuma ko ciwon daji ya daidaita zuwa wurare masu nisa (M). Matakan sun bambanta daga I (mataki na farko) zuwa IV (ci gaba mataki) .Gwajin kwayoyin halitta don gwajin NSCLCMolecular yana gano takamaiman maye gurbin kwayoyin halitta ko rashin lafiyar furotin a cikin ƙwayoyin tumor. Wadannan masu amfani da kwayoyin halitta zasu iya taimakawa wajen ƙayyade idan mai haƙuri ya kasance dan takara don hanyoyin kwantar da hankali. Maye gurbin gama gari sun haɗa da EGFR, ALK, ROS1, BRAF, da sauransu. Sakamakon gwajin kwayoyin halitta yana tasiri sosai ga shawarwarin jiyya.Standard Magungunan NSCLCTiyataSurgery galibi shine jiyya ta farko don matakin farko na NSCLC (mataki na I da II). Manufar ita ce a cire ciwace-ciwacen daji da kowane nau'in lymph na kusa. Nau'in tiyata sun haɗa da: Tsawon tsinke: Cire ƙaramin yanki na huhu mai siffa mai siffa. Segmentectomy: Cire babban ɓangaren huhu fiye da jujjuyawar yanki. Lobectomy: Cire gaba ɗaya lobe na huhu. Wannan ita ce mafi yawan aikin fiɗa ga NSCLC. Pneumonectomy: Cire dukkan huhu. Wannan ba shi da yawa kuma an tanada shi don ƙarin ciwace-ciwacen daji.Radiation TherapyRadiation far yana amfani da haskoki masu ƙarfi don kashe ƙwayoyin cutar kansa. Ana iya amfani da shi azaman magani na farko, bayan tiyata don kashe duk wasu ƙwayoyin cutar kansa, ko don kawar da alamun cutar (palliative radiation). Daban-daban na maganin radiation sun haɗa da: External Beam Radiation Therapy (EBRT): Ana isar da radiation daga na'ura a wajen jiki. Stereotactic Jikin Radiation Therapy (SBRT): Yana ba da babban allurai na radiation zuwa ƙaramin yanki, daidai yankin da aka yi niyya. Yawancin lokaci ana amfani da shi don matakin farko na NSCLC lokacin da tiyata ba zaɓi bane. Brachytherapy (Farin Radiation na Ciki): Ana sanya kayan aikin rediyo kai tsaye a cikin ƙari ko kusa da shi.ChemotherapyChemotherapy yana amfani da kwayoyi don kashe ƙwayoyin cutar kansa a cikin jiki. Ana amfani da shi sau da yawa a hade tare da tiyata ko maganin radiation, ko azaman magani na farko don ci gaba Bayanin NSCLC. Magungunan chemotherapy na yau da kullun na NSCLC sun haɗa da cisplatin, carboplatin, paclitaxel, docetaxel, pemetrexed, da gemcitabine.Targeted Therapy for Magungunan NSCLCMagungunan da aka yi niyya su ne magunguna waɗanda ke kai hari kan takamaiman ƙwayoyin cuta da ke cikin haɓakar ƙwayoyin cutar kansa da rayuwa. Wadannan hanyoyin kwantar da hankali suna da tasiri ne kawai idan ƙari yana da takamaiman maye gurbin kwayoyin halitta ko rashin lafiyar furotin. EGFR InhibitorsEGFR (epidermal growth factor receptor) ana amfani da masu hanawa don magancewa. Bayanin NSCLC tare da maye gurbin EGFR. Wadannan kwayoyi suna toshe furotin EGFR, wanda ke taimakawa kwayoyin cutar kansa girma. Misalan sun haɗa da: Gefitinib (Iressa) Erlotinib (Tarceva) Afatinib (Gilotrif) Osimertinib (Tagrisso) ALK InhibitorsALK (anaplastic lymphoma kinase) inhibitors ana amfani da su don magance su. Bayanin NSCLC tare da sake tsarin ALK gene. Wadannan magungunan suna toshe furotin ALK, wanda ke taimakawa kwayoyin cutar kansa girma. Misalan sun haɗa da: Crizotinib (Xalkori) Ceritinib (Zykadia) Alectinib (Alecensa) Brigatinib (Alunbrig) Lorlatinib (Lorbrena) ROS1 InhibitorsROS1 masu hanawa ana amfani da su don magance su. Bayanin NSCLC tare da sake tsara halittar ROS1. Waɗannan magungunan suna toshe furotin ROS1, wanda ke taimakawa ƙwayoyin cutar kansa girma. Misalai sun haɗa da: Crizotinib (Xalkori) Entrectinib (Rozlytrek) BRAF Inhibitors Ana amfani da masu hanawa na BRAF don magancewa. Bayanin NSCLC tare da maye gurbin BRAF V600E. Wadannan kwayoyi suna toshe furotin BRAF. Misalai sun haɗa da: Dabrafenib (Tafinlar) Trametinib (Mekinist) (amfani da haɗin gwiwa tare da Dabrafenib)Sauran hanyoyin kwantar da hankali da aka yi niyya za a iya amfani da wasu hanyoyin da aka yi niyya dangane da takamaiman maye gurbi da ke cikin ƙwayar cuta. Misalai sun haɗa da masu hana RET (na RET fusions) da masu hana MET (don MET exon 14 skipping maye gurbi).Immunotherapy don Magungunan NSCLCMagungunan rigakafi na taimaka wa tsarin garkuwar jiki don yakar ciwon daji. Suna aiki ta hanyar toshe sunadaran da ke hana tsarin rigakafi daga kai hari kan ƙwayoyin cutar kansa. Ana yawan amfani da waɗannan a cikin Bayanin NSCLC jiyya.PD-1/PD-L1 InhibitorsPD-1 (tsarin furotin mutuwar kwayar halitta 1) da PD-L1 (tsarin mutuwa-ligand 1) masu hanawa sun toshe hanyar PD-1 / PD-L1, wanda ke taimakawa ƙwayoyin ciwon daji su guje wa tsarin rigakafi. Misalan sun haɗa da: Pembrolizumab (Keytruda) Nivolumab (Opdivo) Atezolizumab (Tecentriq) Durvalumab (Imfinzi) Cemiplimab (Libtayo) CTLA-4 InhibitorsCTLA-4 (cytotoxic T-lymphocyte-haɗe da furotin 4) masu hana ƙwayoyin cuta-4 da ke hana ƙwayoyin cutar kansa. Misali shine Ipilimumab (Yervoy), galibi ana amfani dashi tare da masu hana PD-1. Magungunan NSCLC ya haɗa da haɗakar magunguna daban-daban. Misali, tiyata na iya biyo baya ta hanyar chemotherapy ko radiation far. Ana iya haɗa maganin da aka yi niyya ko immunotherapy tare da chemotherapy. Haɗin takamammen zai dogara ne akan yanayin mutum ɗaya. Don neman ƙarin bayani game da binciken cutar daji ziyarci Shandong Baofa Cibiyar Nazarin Ciwon dajiGwajin asibiti Gwajin asibiti binciken bincike ne da ke kimanta sabbin jiyya ko haɗuwar jiyya. Marasa lafiya da Bayanin NSCLC na iya yin la'akari da shiga cikin gwaje-gwaje na asibiti don samun damar hanyoyin kwantar da hankali. Ana iya samun bayanai game da gwaje-gwajen asibiti akan gidan yanar gizon Cibiyar Ciwon daji ta ƙasa da sauran tushe masu inganci. Magungunan NSCLC na iya haifar da illa. Yana da mahimmanci a tattauna yiwuwar illa tare da likitan ku kuma ku koyi yadda ake sarrafa su. Kulawa da tallafi, irin su kula da ciwo da tallafin abinci mai gina jiki, na iya taimakawa wajen inganta rayuwar rayuwa a lokacin jiyya. Bayanin NSCLC ya danganta da matakin ciwon daji, da lafiyar majiyyaci, da yadda ciwon daji ke amsawa ga magani. Alƙawuran bin diddigin na yau da kullun suna da mahimmanci don saka idanu don sake dawowa da sarrafa duk wani sakamako na dogon lokaci na jiyya.Disclaimer: Wannan labarin yana ba da cikakken bayani game da maganin ciwon huhu na ƙananan ƙwayoyin cuta (NSCLC). kuma bai kamata a yi la'akari da shawarar likita ba. Koyaushe tuntuɓi likitan ku ko wasu ƙwararrun ƙwararrun ƙwararrun kiwon lafiya don keɓaɓɓen shawarwari game da takamaiman yanayin lafiyar ku.